Skip to main content

Advertisement

SpringerLink
Log in

Diagnosis and Treatment of Childhood Migraine

  • Pediatric Neurology (R-M Boustany, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

While the diagnosis of migraine in children is generally straightforward, treatment can seem complex with a number of medication choices, many of which are used “off label.” Patients with intermittent migraines can often be managed with ibuprofen or naproxen taken as needed. Unfortunately, by the time that children present to our practice, they have often tried these medications without improvement. Triptans are frequently prescribed to these patients with good success. It is important to make the patient aware of the possible associated serotonergic reactions. If the patient is having more than one headache per week or the headaches are prolonged, prophylactic treatment is indicated. In our practice, the overwhelming majority of these patients will be treated with amitriptyline or topiramate. We generally allow side effect tolerability to guide our choice of medication. Cyproheptadine is often used in younger patients as it comes in a liquid form. There is evidence supporting the use of propranolol, though the potential worsening of underlying asthma symptoms may limit its use, and sodium valproate, which must be used with caution in female patients of childbearing age due to significant teratogenicity risks. Other prophylactic treatments with less robust evidence include the antiepileptic drugs gabapentin, zonisamide, and levetiracetam; calcium channel blockers such as verapamil and amlodipine; and the angiotensin receptor blocking agent candasartin (not available in the USA). Almost all patients in our practice are advised to take magnesium supplementation. Magnesium is a supplement with relatively few adverse effects and good evidence for improvement of migraine symptoms. We evaluate lifestyle issues and comorbidities in all our patients. Ignoring these will make successful treatment near impossible. Good sleep, adequate hydration, appropriate diet, and exercise are vitally important. Finally, most of our patients benefit from a psychology evaluation with cognitive behavioral therapy. Stress management and biofeedback are tremendously helpful in improving quality of life in migraineurs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Edmeads J. The treatment of headache: a historical perspective. In: Gallagher RM, editor. Therapy for headache. New York: Marcel Dekker INC; 1990. p. 1–8.

    Google Scholar 

  2. Patterson SM, Silberstein SD. Sometimes Jello helps: perceptions of headache etiology, triggers and treatment in literature. Headache. 1993;33(2):76–81.

    Article  CAS  PubMed  Google Scholar 

  3. Bille B. Migraine in pediatric school children. Acta Paediatr Scand. 1962;51 Suppl 136:1–151.

    Google Scholar 

  4. Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52(12):1088–97.

    Article  PubMed  Google Scholar 

  5. Wöber-Bingöl C. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep. 2013;17(6):341.

    Article  PubMed  Google Scholar 

  6. Genizi J, Matar AK, Zelnik N, Schertz M, Srugo I. Frequency of pediatric migraine with aura in a clinic-based sample. Headache. 2016;56(1):113–7.

    Article  PubMed  Google Scholar 

  7. Lipton RB, Manack A, Ricci JA, Chee E, Turkel CC, Winner P. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache. 2011;51(5):693–706.

    Article  PubMed  Google Scholar 

  8. Pacheva IH, Ivanov IS. Migraine variants—occurrence in pediatric neurology practice. Clin Neurol Neurosurg. 2013;115(9):1775–83.

    Article  PubMed  Google Scholar 

  9. Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011;51(7):1058–77.

    Article  PubMed  Google Scholar 

  10. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703–11.

    Article  CAS  PubMed  Google Scholar 

  11. Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456–70.

    Article  PubMed  Google Scholar 

  12. Rothner AD. The evaluation of headaches in children and adolescents. Semin Pediatr Neurol. 1995;2(2):109–18.

    Article  CAS  PubMed  Google Scholar 

  13. Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006;46(5):766–72.

    Article  PubMed  Google Scholar 

  14. Rutten JK, Lesnick Oberstein SAJ. CADASIL. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews. Seattle: University of Washington; 2000. {Internet}. updated 2016 Jul 14.

    Google Scholar 

  15. Rimkus Cde M, Andrade CS, Leite C, McKinney AM, Lucato LT. Toxic leukoencephalopathies, including drug, medication, environmental and radiation-induced encephalopathic syndromes. Semin Ultrasound CT MR. 2014;35(2):97–117.

    Article  PubMed  Google Scholar 

  16. De Giorgis V, Veggiotti P. GLUT1 deficiency syndrome 2013: current state of the art. Seizure. 2013;22(10):802–11.

    Article  Google Scholar 

  17. Edmond JC. Mitochondrial disorders. Int Ophthalmol Clin. 2009;49(3):27–33.

    Article  PubMed  Google Scholar 

  18. Stuart S, Griffiths LR. A possible role for mitochondrial dysfunction in migraine. Mol Genet Genomics. 2012;287(11-12):837–44.

    Article  CAS  PubMed  Google Scholar 

  19. Sparaco M, Felena M, Lipton RB, Rapoport AM, Bigal ME. Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia. 2006;26:361–72.

    Article  CAS  PubMed  Google Scholar 

  20. Wong F, Rayner-Hartley E, Byrne MF. Extraintestinal manifestations of Helicobacter pylori: a concise review. World J Gatroenterol. 2014;20(34):11950–61.

    Article  Google Scholar 

  21. Spillane J, Kullmann DM, Hanna MG. Genetic neurological channelopathies: molecular genetics and clinical phenotypes. J Neurol Neurosurg Psychiatry. 2016;87(1):37–48.

    CAS  PubMed  Google Scholar 

  22. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808. This is the most recent version of the internationally accepted headache classification, including descriptions of each entity.

    Article  Google Scholar 

  23. Rothner AD, Parikh S. Migraine variants or episodic syndromes that may be associated with migraine and other unusual pediatric headache syndromes. Headache. 2016;56(1):206–14.

    Article  PubMed  Google Scholar 

  24. Ducros A, Joutel A, Vahedi K, et al. Mapping of a second locus for familial hemiplegic migraine to 1q21-q23 and evidence of further heterogeneity. Ann Neurol. 1997;42(6):885–90.

    Article  CAS  PubMed  Google Scholar 

  25. Gardiner AR, Bhatia KP, Stamelou M, et al. PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology. 2012;79(21):2115–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cloarec R, Bruneau N, Rudolf G, et al. PRRT2 links infantile convulsions and paroxysmal dyskinesia with migraine. Neurology. 2012;79(21):2097–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Zaki EA, Freilinger T, Klopstock T, et al. Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome. Cephalalgia. 2009;29(7):719–28.

    Article  CAS  PubMed  Google Scholar 

  28. Fenichel GM. Clinical pediatric neurology: a signs and symptoms approach. 6th ed. Philadelphia: Saunders Elsevier; 2009.

    Google Scholar 

  29. Goadsby PJ. Pathophysiology of migraine. Ann Indian Acad Neurol. 2012;15 Suppl 1:S15–22.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Peroutka SJ. What turns on a migraine? A systematic review of migraine precipitating factors. Curr Pain Headache Rep. 2014;18(10):454.

    Article  PubMed  Google Scholar 

  31. Arruda MA, Arruda R, Guidetti V, Bigal ME. Psychosocial adjustment of children with migraine and tension-type headache—a nationwide study. Headache. 2015;55 Suppl 1:39–50.

    Article  PubMed  Google Scholar 

  32. Masruha MR, Lin J, Minett TS, et al. Social anxiety score is high in adolescents with chronic migraine. Pediatr Int. 2012;54(3):393–6.

    Article  PubMed  Google Scholar 

  33. Pavone P, Rizzo I, Conti I, et al. Primary headaches in children: clinical findings on the association with other conditions. Int J Immunopathol Pharmacol. 2012;25(4):1083–91.

    CAS  PubMed  Google Scholar 

  34. Pakalnis A, Gibson J, Colvin A. Comorbidity of psychiatric and behavioral disorders in pediatric migraine. Headache. 2005;45(4):590–6.

    Article  PubMed  Google Scholar 

  35. Toldo I, Perissinotto E, Menegazzo F, et al. Comorbidity between headache and epilepsy in a pediatric headache center. J Headache Pain. 2010;11(3):235–40.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Seidel S, Böck A, Schlegal W, et al. Increased RLS prevalence in children and adolescents with migraine: a case-control study. Cephalalgia. 2012;32(9):693–9.

    Article  PubMed  Google Scholar 

  37. Boccia G, Del Giudice E, Crisanti AF, Strisciuglio C, Romano A, Staiano A. Functional gastrointestinal disorders in migrainous children: efficacy of flunarizine. Cephalalgia. 2006;26(10):1214–9.

    Article  CAS  PubMed  Google Scholar 

  38. Hämäläinen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997;48(1):103–7.

    Article  PubMed  Google Scholar 

  39. Tepper DE. Non-steroidal anti-inflammatories for the acute treatment of migraine. Headache. 2012;53(1):225–6.

    Article  Google Scholar 

  40. Boureau F, Kappos L, Schoenen J, Esperanca P, Ashford E. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract. 2000;54(5):281–6.

    CAS  PubMed  Google Scholar 

  41. Fujita M, Sato K, Nishioka H, Sakai F. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. Cephalalgia. 2014;34(5):365–75.

    Article  PubMed  Google Scholar 

  42. Winner P, Rothner AD, Wooten JD, Webster C, Ames M. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache. 2006;46(2):212–22.

    Article  PubMed  Google Scholar 

  43. Lewis DW, Winner P, Hershey AD, Wasiewski WW, Adolescent Migraine Steering Committee. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics. 2007;120(2):390–6.

    Article  PubMed  Google Scholar 

  44. Evers S, Rahmann A, Kraemer C, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology. 2006;67(3):497–9.

    Article  CAS  PubMed  Google Scholar 

  45. Winner P, Linder SL, Lipton RB, Almas M, Parsons B, Pitman V. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache. 2007;47(4):511–8.

    Article  PubMed  Google Scholar 

  46. Ho TW, Pearlman E, Lewis D, et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia. 2012;32(10):750–65.

    Article  PubMed  Google Scholar 

  47. Sun H, Bastings E, Temeck J, et al. Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents. JAMA Pediatr. 2013;167(3):243–9. Triptans are the most widely used abortive medications for migraine. This is an excellent review of their use in pediatric patients and the difficulty in evaluating their efficacy.

    Article  PubMed  Google Scholar 

  48. Johnson HF, Goadsby PJ, Gelfand AA. Predictors of triptan response in pediatric migraine. Pediatr Neurol. 2016. [Epub ahead of print].

  49. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50(6):1089–99.

    Article  PubMed  Google Scholar 

  50. Klapper J, Mathew N, Nett R. Triptans in the treatment of basilar migraine and migraine with prolonged aura. Headache. 2001;41(10):981–4.

    Article  CAS  PubMed  Google Scholar 

  51. Mathew PG, Krel R, Buddhdev B, et al. A retrospective analysis of triptan and DHE use for basilar and hemiplegic migraine. Headache. 2016. [Epub ahead of print].

  52. Lakshmi CV, Singhi P, Malhi P, Ray M. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol. 2007;22(7):829–35.

    Article  CAS  PubMed  Google Scholar 

  53. Fallah R, Divanizadeh MS, Karimi M, Mirouliaei M, Shamszadeh A. Topiramate and propranolol for prophylaxis of migraine. Indian J Pediatr. 2013;80(11):920–4.

    Article  PubMed  Google Scholar 

  54. Ashrafi MR, Shabanian R, Zamani GR, Mahfelati F. Sodium valproate versus propranolol in paediatric migraine prophylaxis. Eur J Pediatr Neurol. 2005;9(5):333–8.

    Article  CAS  Google Scholar 

  55. Bidabadi E, Mashouf M. A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. Paediatr Drugs. 2010;12(4):269–75.

    Article  PubMed  Google Scholar 

  56. Bille B, Ludvigsson J, Sanner G. Prophylaxis of migraine in children. Headache. 1977;17:61–3.

    Article  CAS  PubMed  Google Scholar 

  57. Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache. 2003;43(6):601–10.

    Article  PubMed  Google Scholar 

  58. MacLennan SC, Wade FM, Forrest KM, Ratanayake PD, Fagan E, Antony J. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol. 2008;23(11):1300–4.

    Article  PubMed  Google Scholar 

  59. Cayir A, Turan MI, Tan H. Effect of vitamin D therapy in addition to amitriptyline on migraine attacks in pediatric patients. Braz J Med Biol Res. 2014;47(4):349–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Kroner JW, Hershey AD, Kashikar-Zuck SM, et al. Cognitive behavioral therapy plus amitriptyline for children and adolescents with chronic migraine reduces headache days to ≤4 per month. Headache. 2016;56(4):711–6. An excellent study reinforcing the benefit of cognitive behavioral therapy for pediatric migraineurs.

    Article  PubMed  Google Scholar 

  61. Kabbouche MA. Management of pediatric migraine headache in the emergency room and infusion center. Headache. 2015;55(10):1365–70. A comprehensive review of ER treatment options for pediatric migraineurs.

    Article  PubMed  Google Scholar 

  62. Sheridan DC, Spiro DM, Meckler GD. Pediatric migraine: abortive management in the emergency department. Headache. 2014;54(2):235–45.

    Article  PubMed  Google Scholar 

  63. Gelfand AA, Goadsby PJ. Treatment of pediatric migraine in the emergency room. Pediatr Neurol. 2012;47(4):233–41.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Leung S, Bulloch B, Young C, Yonker M, Hostetler M. Effectiveness of standardized combination therapy for migraine treatment in the pediatric emergency department. Headache. 2013;53(3):491–7.

    Article  PubMed  Google Scholar 

  65. Legault G, Eisman H, Shevell M. Treatment of pediatric status migrainosus: can we prevent the “bounce back”? J Child Neurol. 2011;26(8):949–55.

    Article  PubMed  Google Scholar 

  66. Trottier ED, Bailey B, Lucas N, Lortie A. Prochlorperazine in children with migraine: a look at its effectiveness and rate of akathisia. Am J Emerg Med. 2012;30(3):456–63.

    Article  PubMed  Google Scholar 

  67. Kabbouche MA. Pediatric inpatient headache therapy: what is available. Headache. 2015;55(10):1426–9. As with #61 above, a comprehensive review of inpatient therapy.

    Article  PubMed  Google Scholar 

  68. Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache. 1994;34(10):578–80.

    Article  CAS  PubMed  Google Scholar 

  69. Winner P, Lewis DW, Rothner AD. Headache in children and adolescents. 2nd ed. New York: BC Decker; 2008.

    Google Scholar 

  70. O’Brien HL, Kabbouche MA, Kacperski J, Hershey AD. Treatment of pediatric migraine. Curr Treat Options Neurol. 2015;17(1):1–17.

    Article  Google Scholar 

  71. Hershey AD, Powers SW, Winner P, Kabbouche MA. Pediatric headache in clinical practice. West Sussex: Wiley-Blackwell; 2009.

    Book  Google Scholar 

  72. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–7.

    Article  CAS  PubMed  Google Scholar 

  73. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48–56.

    Article  CAS  PubMed  Google Scholar 

  74. Hansen JM, Hauge AW, Oesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179–86.

    Article  PubMed  Google Scholar 

  75. Rizzoli PB. Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan. Neuropsychiatr Dis Treat. 2014;10:547–52.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Child Neurology, Nationwide Children’s Hospital, Columbus, OH, USA

    Kelsey Merison MD

  2. Division of Child Neurology, Ohio State University, Nationwide Children’s Hospital, FB, Suite 4A.4-4814, 700 Children’s Drive, Columbus, OH, 43205, USA

    Howard Jacobs MD

Authors
  1. Kelsey Merison MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard Jacobs MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard Jacobs MD.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Pediatric Neurology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Merison, K., Jacobs, H. Diagnosis and Treatment of Childhood Migraine. Curr Treat Options Neurol 18, 48 (2016). https://doi.org/10.1007/s11940-016-0431-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-016-0431-4

Keywords

Search

Navigation